Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn’s Disease and Ulcerative Colitis

Digestive Diseases and Sciences

Volumn 62, Issue 9, 2017, Pages 2348-2356

  Lazaridis, Lazaros Dimitrios ^a   Pistiki, Aikaterini ^a   Giamarellos Bourboulis, Evangelos J ^a   Georgitsi, Marianna ^a   Damoraki, Georgia ^a   Polymeros, Dimitrios ^a   Dimitriadis, George D ^a   Triantafyllou, Konstantinos ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

ATG16L1; Crohn s disease; IBD; NLRP3 inflammasome; Ulcerative colitis

Indexed keywords

AUTOPHAGY RELATED PROTEIN; AUTOPHAGY RELATED PROTEIN 16L1; AZATHIOPRINE; CRYOPYRIN; DNA; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; METHOTREXATE; RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; NLRP3 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE DURATION; DNA ISOLATION; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INFLAMMATORY BOWEL DISEASE; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPERNATANT; ULCERATIVE COLITIS; WILD TYPE; AGED; COMPARATIVE STUDY; METABOLISM; MONONUCLEAR CELL;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 85019583462     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4609-8     Document Type: Article

References (23)

1. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol. 2011;32:171–179.
2. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550.
3. Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases—lessons learned from experimental models. Cytokine Growth Factor Rev. 2014;25:715–730.
4. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34–42.
5. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–426.
6. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007;7:31–40.
7. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007;27:549–559.
8. Opipari A, Franchi L. Role of inflammasomes in intestinal inflammation and Crohn’s disease. Inflamm Bowel Dis. 2015;21:173–181.
9. Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.
10. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat Genet. 2009;41:71–76.
11. Schoultz I, Verma D, Halfvarsson J, et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn’s disease in Swedish men. Am J Gastroenterol. 2009;104:1180–1188.
12. Lewis GJ, Massey DC, Zhang H, et al. Genetic association between NLRP3 variants and Crohn’s disease does not replicate in a large UK panel. Inflamm Bowel Dis. 2011;17:1387–1391.
13. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohn’s Colitis. 2010;4:7–27.
14. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis (Spanish version). Rev. Gastroenterol. Mex. 2014;79:263–289.
15. Peyrin-Biroulet L, Billioud V, D’Haens G, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107:1770–1776.
16. Seegmiller J, Howell R, Malawista S. The inflammatory reaction of sodium urate. JAMA. 1962;180:469–475.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408.
18. Mylona EE, Mouktaroudi M, Crisan TO, et al. Enhanced interleukin-1beta production of PBMCs from patients with gout after stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther. 2012;14:R158.
19. Kim JM. Inflammatory bowel diseases and inflammasome. Korean J Gastroenterol. 2011;58:300–310.
20. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289–298.
21. Yang SK, Kim H, Hong M, et al. Association of CARD8 with inflammatory bowel disease in Koreans. J Hum Genet. 2011;56:217–223.
22. Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J Clin Rheumatol. 2003;9:276–277.
23. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn’s disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009;9:22.